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Summary
Background Gaps in the diagnostic capacity and heterogeneity of national surveillance and reporting standards in 
Europe make it diﬃ  cult to contain carbapenemase-producing Enterobacteriaceae. We report the development of a 
consistent sampling framework and the results of the ﬁ rst structured survey on the occurrence of carbapenemase-
producing Klebsiella pneumoniae and Escherichia coli in European hospitals.
Methods National expert laboratories recruited hospitals with diagnostic capacities, who collected the ﬁ rst ten 
carbapenem non-susceptible clinical isolates of K pneumoniae or E coli and ten susceptible same-species comparator 
isolates and pertinent patient and hospital information. Isolates and data were relayed back to national expert 
laboratories, which made laboratory-substantiated information available for central analysis. 
Findings Between Nov 1, 2013, and April 30, 2014, 455 sentinel hospitals in 36 countries submitted 2703 clinical 
isolates (2301 [85%] K pneumoniae and 402 (15%) E coli). 850 (37%) of 2301 K pneumoniae samples and 77 (19%) of 402 E coli 
samples were carbapenemase (KPC, NDM, OXA-48-like, or VIM) producers. The ratio of K pneumoniae to E coli was 
11:1. 1·3 patients per 10 000 hospital admissions had positive clinical specimens. Prevalence diﬀ ered greatly, with the 
highest rates in Mediterranean and Balkan countries. Carbapenemase-producing K pneumoniae isolates showed high 
resistance to last-line antibiotics. 
Interpretation This initiative shows an encouraging commitment by all participants, and suggests that challenges in 
the establishment of a continent-wide enhanced sentinel surveillance for carbapenemase-producing Entero-
bacteriaeceae can be overcome. Strengthening infection control eﬀ orts in hospitals is crucial for controlling spread 
through local and national health care networks.
Funding European Centre for Disease Prevention and Control.
Introduction 
Carbapenemase-producing Enterobacteriaceae (CPE) are 
the most pervasive antibiotic resistance threat to health 
services worldwide. Because of the dearth of alternative 
drugs, patients are often left without eﬀ ective treatment, 
revealing burgeoning resistance, long concealed by 
adaptive prescribing when doctors could still choose 
carbapenems as a last-line drug. Therefore, spread of CPE 
could be the tipping point when substantial morbidity and 
mortality from antibiotic resistance comes to the fore.1
Few alternative antibiotics (eg, colistin, fosfomycin, 
and tigecycline) remain,2 and although resistance can 
extend even to agents still in development or recently 
approved,3,4 public health eﬀ orts are beginning to 
emphasise containment of CPE in populations and 
health-care networks. This requires an understanding of 
the geographical distribution of CPE infections, their 
population reservoirs, and the risk factors for acquisition. 
However, there is little internationally comparable data.
The European Survey on CPE (EuSCAPE) was initiated 
with the aim of providing the ﬁ rst comparable and 
quality-controlled data on the occurrence of the most 
important CPE (Klebsiella pneumoniae and Escherichia coli) 
in Europe and neighbouring countries, and to establish a 
framework for future enhanced sentinel surveillance. It 
entailed the stepwise build-up of structures through 
identiﬁ cation of national expert laboratories (NELs),5 a 
joint agreement on diagnostic standards, improvement 
of quality-assessed diagnostic capacity among NELs, and, 
as a proof of feasibility, a structured survey using a 
standard sampling protocol in all participating sites. We 
describe the execution and ﬁ nal results of the EuSCAPE 
structured survey.
Methods 
Capacity building and proﬁ ciency testing 
Technical staﬀ  from all NELs were trained to use a set of 
standard phenotypic and genotypic tests in accordance 
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with EUCAST guidelines.6 Subsequently, all NELs were 
required to take part in an external quality assessment 
exercise, which was carried out and analysed by the UK 
National External Quality Assessment Service. Successful 
completion was a prerequisite for participation.
Structured survey 
Each NEL recruited a deﬁ ned number of hospitals with 
microbiologic diagnostic capacity, depending on the 
country’s population; 20 sites were recruited in large 
countries (>15 million population), ten sites in medium-
sized countries (2–15 million population), and one site in 
small countries (<2 million population). To prevent 
geographical bias, the NELs were asked to enrol hospitals 
in a geo-demographical representative manner (ﬁ gure, 
appendix). NELs were asked to collect additional 
information about the participating hospitals for 2013, 
including number of beds, annual number of admissions, 
total number of patient-days, average bed occupancy, 
average length of stay, and estimated size of catchment 
population.
The sampling period was 6 months, starting on 
Nov 1, 2013, and ending on April 30, 2014. During this 
period, each sentinel site was required to collect the ﬁ rst 
ten consecutive primary isolates of K pneumoniae or E coli 
from clinical specimens from individual patients if local 
routine tests showed non-susceptibility to any carba-
penem (imipenem, meropenem, or ertapenem). All 
clinical specimens were accepted, except for stool and 
surveillance screening samples. Each index isolate (ie, 
carbapenem-non-susceptible K pneumoniae or E coli) was 
matched to the ﬁ rst subsequent carbapenem-susceptible 
isolate of the same species irrespective of anatomical site, 
serving as a comparator isolate.
Isolates were dispatched to the NEL with additional 
information including sample date, anatomical origin of 
specimen, patient age and sex, clinical relevance of the 
isolate (colonisation or infection), patient location in the 
hospital (intensive care unit, ordinary ward, outpatient, 
or accident and emergency), and hospital admission and 
travel outside their country of residence in the past 
6 months. Hospital acquisition was inferred when an 
isolate was sampled from patients after being admitted 
for more than 48 h, or community-associated otherwise. 
Instructions on the collection of isolates, and the 
ascertainment of clinical and epidemiological data were 
given by the structured survey protocol (appendix), which 
was translated by NELs into their respective language 
and distributed to the sentinel hospital laboratories if 
necessary.
The NELs conﬁ rmed species and phenotypic 
susceptibility and used PCR tests for four carbapenemase 
gene families (Klebsiella pneumoniae carbapenemase 
[KPC], New Delhi metallo-β-lactamase [NDM], 
oxacillinase-48 [OXA-48-like], or Verona integron-
encoded metallo-β-lactamase [VIM]). Antimicrobial 
susceptibility tests according to EUCAST guidelines 
variously included ampicillin, amoxicillin and clavulanic 
acid, piperacillin and tazobactam, cefotaxime, cefta-
zidime, cefepime, aztreo nam, imipenem, mero penem, 
ertapenem, cipro ﬂ oxacin, trimethoprim and sulfa-
methoxazole (co-trimoxazole), genta micin, amikacin, 
tobramycin, tigecycline, colistin, and fosfo mycin. Pheno-
typic conﬁ rmation of carbapenemase production 
consisted of double disk synergy tests, com bin ation disk 
tests, and Carba NP I or II test.7 Metho dological details 
for these tests are described in the appendix. Carbapenem 
non-susceptible isolates that were tested PCR-negative 
Research in context
Evidence before this study
On April 1, 2016, we search Pubmed with the terms 
“carbapenemase-producing Enterobacteriaceae” or 
“carbapenem-resistant Enterobacteriaceae”, or “Klebsiella 
pneumoniae”, “Escherichia coli”, “Europe” and “surveillance” for 
reports published between Jan 1, 2000 and Jan 1, 2016, with no 
language restrictions. This search identiﬁ ed 72 publications. 
These consisted of larger national surveillance studies, reviews, or 
single case studies. None of the studies included comprehensive 
European coverage, standardisation of methods, or diagnostic 
quality assessment. Before this study, only anecdotal evidence 
existed for several countries with high endemicity. Since national 
reference laboratory structures were often absent and diagnostic 
standards diﬀ ered between laboratories, cases remained 
unconﬁ rmed leaving wide scope for ascertainment bias.
Added value of this study
We report data on the occurrence of carbapenemase-
producing and last-line antibiotic resistant K pneumoniae and 
E coli using standardised procedures and provide the ﬁ rst 
comparable and laboratory-substantiated data on the 
incidence of these diﬃ  cult-to-treat bacteria across Europe.
Implications of all the available evidence
K pneumoniae of nosocomial provenance is the main source of 
carbapenemase-producing Enterobacteriaeceae (CPE) 
infection in Europe. The emergence and spread of antibiotic 
resistance against last-line antibiotics increasingly erodes the 
ability to successfully treat patients infected with CPE 
especially in countries where CPE prevalence in hospitals is 
high. At a time when novel and eﬀ ective antibiotic 
compounds have not become available, containment of CPE is 
bound to rely on stricter infection control measures in 
hospitals. 
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were classiﬁ ed as “other”. Results and epidemiological 
information were uploaded for central analysis using a 
password-protected web tool.
All data were anonymised and collected in accordance 
with the European Parliament and Council decisions on 
the epidemiological surveillance and control of com-
municable disease in the European Community.8,9 Ethical 
approval and informed consent were thus not required.
Data analysis 
Data were analysed with STATA version 13.1 (StataCorp, 
Texas, USA) using Mantel-Haenzel odds ratios and 
Pearson χ² test for univariate risk factor analysis and 
multiple logistic regression for multivariable analysis 
with log likelihood ratio tests after ﬁ tting interaction 
terms to identify eﬀ ect modiﬁ cation. For hospitals that 
could not provide ﬁ gures on the total number of patient 
days in 2013, we estimated this value as the product of 
the number of admissions and the average length of stay. 
Country-aggregated period prevalence estimates were 
reported as number of patients diagnosed with either 
carbapenemase-producing K pneumoniae or E coli per 
10 000 hospital admissions. Country-aggregated 
incidence estimates were reported as number of patients 
diagnosed with either carbapenemase-producing 
K pneumoniae or E coli per 100 000 hospital patient-days. 
Conﬁ dence intervals for random errors are not provided 
because of heterogeneity of sampling density as a result 
of diﬀ erent diagnostic habits.
Role of the funding source 
The study was funded by the European Centre for 
Disease Prevention and Control (ECDC) through a 
speciﬁ c framework service contract (ECDC/2012/055) to 
the University Medical Center Groningen, Groningen, 
Netherlands. ECDC provided comments on the study 
design, suggested national coordinators, and provided 
comments on the analysis and the ﬁ nal report. The 
decision to submit for publication was jointly taken by all 
contributors.
Results 
Between Nov 1, 2013, and April 30, 2014, 455 sentinel 
hospitals from 36 countries contributed to the 
Figure: Locations of participating sentinel hospitals 
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structured survey (ﬁ gure). Participating countries 
included 27 Euro pean Union Member States, two 
European Eco nomic Area countries, and six EU 
enlargement countries plus Israel. In the UK, Scotland 
participated on its own behalf. Albania, Finland, 
Israel, Latvia, Macedonia, Romania, Slovakia, Turkey, 
and the UK (England and Northern Ireland) did not 
reach their quota of parti ci pating sentinel hospitals, 
but Belgium, Bulgaria, Croatia, France, Hungary, Italy, 
Kosovo, Luxembourg, Norway, Poland, Portugal, 
Klebsiella pneumoniae Escherichia coli Sentinel 
hospitals 
(mean beds†)
Incidence per 10 000 
admissions‡
Incidence per 100 000 
patient-days§
Submitted 
non-
susceptible 
isolates (n)
Conﬁ rmed 
carbapenemase-
producing 
isolates* (n)
Comparator 
isolates (n)
Submitted 
non-
susceptible 
isolates (n)
Conﬁ rmed 
carbapenemase 
producing 
isolates* (n)
Comparator 
isolates (n)
Rate 
(hospitals)
Rank Rate 
(hospitals)
Rank
Albania 8 0 11 6 0 5 5 (586) .. 25 0 (5) 24
Austria 15 10 15 1 0 1 10 (968) 0 (1) 25 .. ..
Belgium 48 33 49 13 5 13 15 (837) 1·2 (11) 8 1·74 (11) 8
Bulgaria 4 2 4 8 8 8 11 (538) 0·7 (11) 10 1·29 (11) 11
Croatia 48 7 52 2 1 2 32 (714) 0·29 (23) 16 0·44 (22) 18
Cyprus 1 1 1 2 2 2 1 (453) 2·45 (1) 6 4·09 (1) 6
Czech Republic 26 2 9 2 0 0 10 (1460) 0·09 (9) 21 0·14 (9) 21
Denmark 8 6 8 1 1 1 10 (..) .. .. .. ..
Estonia 9 0 8 3 0 3 1 (635) 0 (1) 25 0 (1) 24
Finland 1 0 1 6 0 10 9 (1126) 0 (8) 25 0 (7) 24
France 27 11 26 12 3 14 26 (763) .. .. .. ..
Germany 36 22 36 10 3 10 20 (1189) 0·56 (17) 13 0·6 (1) 16
Greece 86 79 79 1 1 1 10 (407) 5·78 (3) 2 17·3 (3) 1
Hungary 36 26 27 1 0 1 11 (1680) 0·68 (11) 11 1·04 (11) 12
Iceland 0 0 0 0 0 0 1 (612) 0 (1) 25 0 (1) 24
Ireland 12 6 10 10 0 9 10 (528) 0·44 (10) 15 0·67 (10) 15
Israel 39 34 36 6 6 4 8 (669) .. .. .. ..
Italy 195 192 198 5 5 5 22 (740) 5·96 (22) 1 7·8 (22) 3
Kosovo 0 0 0 0 0 0 2 (..) .. .. .. ..
Latvia 4 2 5 0 0 0 1 (826) 0·85 (1) 9 1·68 (1) 9
Lithuania 4 0 4 1 1 1 10 (780) 0·06 (9) 22 0·09¶ (9) 23
Luxembourg 10 8 10 0 0 0 5 (435) 1·45 (5) 7 2·25 (5) 7
Malta 9 9 9 1 1 1 1 (850) .. .. .. ..
Montenegro 10 10 10 0 0 0 1 (760) 5·65 (1) 3 9·27 (1) 2
Norway 5 1 5 5 1 5 45 (253) 0·02 (30) 24 .. ..
Poland 34 4 28 0 0 0 21 (639) 0·15 (17) 19 0·25 (17) 19
Portugal 61 36 33 6 2 4 26 (721) 0·65 (26) 12 1·4¶ (24) 10
Romania 68 61 49 0 0 9 12 (891) .. .. .. ..
Serbia 67 43 46 5 5 5 18 (754) 3 (12) 5 4·35 (12) 5
Slovakia 22 1 22 2 0 2 6 (800) 0·1 (6) 20 0·15 (6) 20
Slovenia 12 3 10 2 0 2 12 (577) 0·25 (10) 17 0·54¶ (8) 17
Spain 116 102 122 14 4 24 20 (696) 4·01 (20) 4 5·88 (20) 4
Sweden 0 0 1 1 1 1 10 (978) .. .. .. ..
Macedonia 3 2 0 0 0 3 2 (1170) 0·51 (2) 14 0·85 (2) 13
Turkey 124 112 130 22 20 20 18 (980) .. .. .. 18
UK-England and 
Northern Ireland
47 25 36 29 6 25 18 (1176) 0·19 (18) 18 0·85¶ (18) 14
UK-Scotland 8 0 8 17 1 17 14 (428) 0·03 (13) 23 0·1 (13) 22
Total or average 1203 850 1098 194 77 208 455 (800) 1·3 (321) .. 2·51 (268) ..
*Conﬁ rmation included genes for the carbapenemase classes KPC, NDM, OXA-48-like, and VIM. †Mean number of beds per hospital for the ﬁ nancial year 2013. ‡Number of hospitals that provided the number of 
admissions per hospital for the ﬁ nancial year 2013. §Number of hospitals that provided the number of admissions and average length of stay for the ﬁ nancial year 2013. ¶For Lithuania, Portugal, Slovenia, and 
UK (England and Northern Ireland), the total number of patient days was calculated as average bed occupancy x number of beds x 365. 
Table 1: Clinical Klebsiella pneumoniae and Escherichia coli isolates submitted by country, and combined incidence estimates in European hospitals 
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Serbia, Slovenia, and UK (Scotland) recruited more 
hospitals. 
During the 6-month period, 2301 K pneumoniae and 
402 E coli isolates were collected (table 1). 1203 (86%) of 
1397 index isolates submitted were K pneumonia, and 
194 (14%) of 1397 isolates were E coli. Proportions of 
index and comparator isolates did not diﬀ er in terms of 
anatomical origin or specimen type except for 
bloodstream infections caused by E coli, for which 
carbapenem-susceptible isolates contributed sub stan-
tially more infections (appendix). Therefore, the ability to 
cause infections seems not to be contingent on the 
resistance traits under study. Of all isolates submitted by 
the NELs as carbapenem non-susceptible, PCR 
Hospitals 
submitting 
carbapenem 
non-susceptible 
K pneumoniae 
isolates (n)
Number of 
submitted 
carbapenem 
non-susceptible 
K pneumoniae 
isolates
Conﬁ rmed carbapenemase-producing K pneumoniae isolates Other 
(n, %)*
KPC (n, %) NDM (n,%) OXA-48-like (n, %) VIM (n, %) Total (n, %)
Albania 3 8 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 8 (100)
Austria 6 15 6 (40·0) 2 (13·3) 2 (13·3) 0 (0) 10 (66·7) 5 (33·3)
Belgium 11 48 13 (27·1) 2 (4·2) 18 (37·5) 0 (0) 33 (68·8) 15 (31·3)
Bulgaria 3 4 0 (0) 2 (50·0) 0 (0) 0 (0) 2 (50·0) 2 (50·0)
Croatia 14 48 1 (2·1) 0 (0) 1 (2·1) 5 (10·4) 7 (14·6) 41 (85·4)
Cyprus 1 1 0 (0) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0)
Czech Republic 5 26 0 (0) 1 (3·8) 1 (3·8) 0 (0) 2 (7·7) 24 (92·3)
Denmark 3 8 1 (12·5) 3 (37·5) 2 (25·0) 0 (0) 6 (75·0) 2 (25·0)
Estonia 1 9 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 9 (100)
Finland 1 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100)
France 11 27 1 (3·7) 0 (0) 10 (37·0) 0 (0) 11 (40·7) 16 (59·3)
Germany 13 36 8 (22·2) 2 (5·6) 12 (33·3) 0 (0) 22 (61·1) 14 (38·9)
Greece 10 86 56 (65·1) 12 (14·0) 2 (2·3) 9 (10·5) 79 (91·9) 7 (8·1)
Hungary 7 36 0 (0) 0 (0) 0 (0) 26 (72·2) 26 (72·2) 10 (27·8)
Ireland 7 12 2 (16·7) 2 (16·7) 2 (16·7) 0 (0) 6 (50·0) 6 (50·0)
Israel 7 39 31 (79·5) 2 (5·1) 1 (2·6) 0 (0) 34 (87·2) 5 (12·8)
Italy 22 195 187 (95·9) 1 (0·5) 1 (0·5) 3 (1·5) 192 (98·5) 3 (1·5)
Latvia 1 4 0 (0) 0 (0) 0 (0) 2 (50·0) 2 (50·0) 2 (50·0)
Lithuania 4 4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (100)
Luxembourg 3 10 4 (40·0) 0 (0) 2 (20·0) 2 (20·0) 8 (80·0) 2 (20·0)
Malta 1 9 0 (0) 0 (0) 9 (100) 0 (0) 9 (100) 0 (0)
Montenegro 1 10 0 (0) 10 (100) 0 (0) 0 (0) 10 (100) 0 (0)
Norway 4 5 0 (0) 1 (20·0) 0 (0) 0 (0) 1 (20·0) 4 (80·0)
Poland 10 34 2 (5·9) 2 (5·9) 0 (0) 0 (0) 4 (11·8) 30 (88·2)
Portugal 17 61 36 (59·0) 0 (0) 0 (0) 0 (0) 36 (59·0) 25 (40·9)
Romania 8 68 4 (5·9) 5 (7·4) 50 (73·5) 2 (2·9) 61 (89·7) 7 (10·3)
Serbia 11 67 1 (·5) 33 (49·3) 9 (13·4) 0 (0) 43 (64·2) 24 (35·8)
Slovakia 5 22 1 (4·5) 0 (0) 0 (0) 0 (0) 1 (4·5) 21 (95·5)
Slovenia 4 12 0 (0) 1 (8·3) 1 (8·3) 1 (8·3) 3 (25·0) 9 (75·0)
Spain 20 116 9 (7·8) 0 (0) 81 (69·8) 12 (10·3) 102 (87·9) 14 (12·1)
Macedonia 1 3 2 (66·7) 0 (0) 0 (0) 0 (0) 2 (66·7) 1 (33·3)
Turkey 17 124 0 (0) 9 (7·3) 98 (79·0) 5 (4·0) 112 (90·3) 12 (9·7)
UK-England and 
Northern Ireland
15 47 14 (29·8) 3 (6·4) 7 (14·9) 1 (2·1) 25 (53·2) 22 (46·8)
UK-Scotland 4 8 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 8 (100)
Total 251 1203 379 (31·5) 93 (7·7) 310 (25·8) 68 (5·7) 850 (70·7) 353 (29·3)
Iceland, Kosovo, and Sweden did not ﬁ nd any K pneumonia isolates that were suspected non-susceptible to carbapenems during the study period. *Other mechanism of 
carbapenem non-susceptibility, since none of the genes coding for the four major types of carbapenemases (KPC, NDM, OXA-48-like and VIM) were detected. All data are n, 
except where otherwise indicated.
Table 2: Klebsiella pneumoniae clinical isolates submitted as non-susceptible to carbapenems, conﬁ rmed as producing a carbapenemase and type of 
carbapenemase, by country 
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conﬁ rmed the presence of KPC, NDM, OXA-48-like, and 
VIM type genes for 850 (71%) of 1203 K pneumoniae 
isolates and 77 (40%) of 194 E coli samples. Among the 
927 carbapenemase-producers, the ratio between K pneu-
moniae and E coli was 11:1.
Country-aggregated prevalence diﬀ ered greatly 
between countries. Based on population-weighted 
averages, 1·3 patients per 10 000 hospital admissions and 
2·5 patients per 100 000 hospital patient-days had a 
carba penemase-producing K pneumoniae or E coli. High 
incidence countries included Greece, Italy, Montenegro, 
Spain, and Serbia.
KPC enzymes were detected in 393 (42%) of 927 CPE 
isolates, and were the most frequent carbapenemases. 
OXA-48-like enzymes were the second most frequent 
(353 [38%] of 927 isolates) and were the most prominent 
class of carbapenemases in eight countries. NDM genes 
were detected in 113 (12%) and VIM in 68 K pneumoniae 
isolates (7%).
In K pneumoniae, the most frequently detected carba-
penemases were KPC enzymes (379 [45%] of 850 isolates), 
followed by OXA-48-like (310 isolates, 37%), NDM (93 
isolates, 11%) and VIM (68 isolates, 8%). In E coli, the 
most frequently detected carbapenemases were 
Hospitals 
submitting 
carbapenem 
non-susceptible 
E coli isolates (n)
Number of 
submitted 
carbapenem 
non-susceptible 
E coli isolates (n)
Conﬁ rmed carbapenemase-producing E coli isolates Other (n, %)*
KPC (n, %) NDM (n, %) OXA-48-like 
(n, %)
VIM (n, %) Total (n, %)
Albania 2 6 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 6 (100)
Austria 1 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100)
Belgium 7 13 0 (0) 1 (7·7) 4 (30·8) 0 (0) 5 (38·5) 8 (61·5)
Bulgaria 1 8 0 (0) 8 (100) 0 (0) 0 (0) 8 (100) 0 (0)
Croatia 2 2 0 (0) 1 (50·0) 0 (0) 0 (0) 1 (50·0) 1 (50·0)
Cyprus 1 2 1 (50·0) 0 (0) 1 (50·0) 0 (0) 2 (100) 0 (0)
Czech Republic 2 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100)
Denmark 1 1 0 (0) 1 (100) 0 (0) 0 (0) 1 (100) 0 (0)
Estonia 1 3 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (100)
Finland 1 6 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 6 (100)
France 10 12 0 (0) 0 (0) 3 (25·0) 0 (0) 3 (25·0) 9 (75·0)
Germany 7 10 0 (0) 1 (10·0) 2 (20·0) 0 (0) 3 (30·0) 7 (70·0)
Greece 1 1 1 (100) 0 (0) 0 (0) 0 (0) 1 (100) 0 (0)
Hungary 1 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100)
Ireland 6 10 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 10 (100)
Israel 3 6 6 (100) 0 (0) 0 (0) 0 (0) 6 (100) 0 (0)
Italy 5 5 4 (80·0) 0 (0) 1 (20·0) 0 (0) 5 (100) 0 (0)
Lithuania 1 1 0 (0) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0)
Malta 1 1 0 (0) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0)
Norway 5 5 0 (0) 0 (0) 1 (20·0) 0 (0) 1 (20·0) 4 (80·0)
Portugal 4 6 2 (33·3) 0 (0) 0 (0) 0 (0) 2 (33·3) 4 (66·7)
Serbia 3 5 0 (0) 5 (100) 0 (0) 0 (0) 5 (100) 0 (0)
Slovakia 2 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100)
Slovenia 1 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100)
Spain 8 14 0 (0) 0 (0) 4 (28·6) 0 (0) 4 (28·6) 10 (71·4)
Sweden 1 1 0 (0) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0)
Turkey 11 22 0 (0) 1 (4·5) 19 (86·4) 0 (0) 20 (90·9) 2 (9·1)
UK-England and 
Northern Ireland
11 29 0 (0) 1 (3·4) 5 (17·2) 0 (0) 6 (20·7) 23 (79·3)
UK-Scotland 5 17 0 (0) 1 (5·9) 0 (0) 0 (0) 1 (5·9) 16 (94·1)
Total 105 194 14 (7·2) 20 (10·3) 43 (22·2) 0 77 (39·7) 117 (60·3)
Iceland, Kosovo, Latvia, Luxembourg, Montenegro, Poland Romania, and Macedonia did not ﬁ nd any E coli isolate that was suspected non-susceptible to carbapenems during 
the study period. *Other mechanism of carbapenem non-susceptibility since none of the genes coding for the four major types of carbapenemases (KPC, NDM, OXA-48-like 
and VIM) were detected. Data are n, unless speciﬁ ed otherwise.
Table 3: Escherichia coli clinical isolates submitted as non-susceptible to carbapenems, conﬁ rmed as producing a carbapenemase and type of 
carbapenemase, by country 
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OXA-48-like enzymes (43 [56%] of 77 isolates) followed by 
NDM (20 isolates, 26%) and KPC (14 isolates, 18%), albeit 
with substantial country-to-country variation in relative 
prevalence (table 2, table 3).
At country level, large proportions of KPC-positive 
K pneumoniae among carbapenem-non-susceptible 
isolates were found in Italy (187 [96%] of 195 isolates), 
Israel (31 [80%] of 39 isolates), Greece (56 [65%] of 
86 isolates), and Portugal (36 [59%] of 61 isolates). These 
four countries, plus Cyprus, were the only countries 
where KPC genes were also detected in E coli, albeit very 
few. OXA-48-like enzymes were common in Turkey, where 
98 (79%) of 124 carbapenem-non-susceptible K pneumonia 
and 19 (86%) of 22 E coli isolates had these enzymes, 
followed by Romania, where 50 (74%) of 68 carbapenem-
non-susceptible K pneumoniae isolates had OXA-48-like 
enzymes. These enzymes were also frequent in Spain 
(81 [70%] of 116), Belgium (18 [38%] of 48), France 
(ten [37%] of 27), and Germany (12 [33%] of 36).
NDM was the most frequent carbapenemase in Serbia 
(33 [49%] of 67 isolates) and in Montenegro, where all 
ten submitted carbapenem non-susceptible K pneu -
moniae isolates were NDM-positive. In Greece, NDM 
was the second most frequent carbapenemase in 
Number of conﬁ rmed 
carbapenemase-producing 
K pneumoniae isolates
Colistin Fosfomycin Tigecycline Total antibiotics 
tested*
Isolates resistant to all 
tested antibiotics (%)
Tested Resistant (%) Tested Resistant (%) Tested Resistant (%)
Austria 10 10 3 (30·0) 10 2 (20·0) 0 ·· 17 1 (10·0)
Belgium 33 0 ·· 0 ·· 0 ·· 12 5 (15·2)
Bulgaria 2 2 0 2 0 2 0 18 0 (0)
Croatia 7 0 ·· 0 ·· 0 ·· 11 2 (28·6)
Cyprus 1 0 ·· 0 ·· 0 ·· 13 0 (0)
Czech Republic 2 2 1 (50·0) 2 0 2 0 18 0 (0)
Denmark 6 0 ·· 0 ·· 0 ·· ·· ··
Estonia 0 0 ·· 0 ·· 0 ·· 18 ··
Finland 0 0 ·· 0 ·· 0 ·· 18 ··
France 11 11 2 (18·2) 11 2 (18·2) 11 1 (9·1) 18 0 (0)
Germany 22 22 8 (36·4) 16 7 (43·8) 22 2 (9·1) 17 0 (0)
Greece 79 21 4 (19·0) 0 ·· 21 4 (19·0) 13 15 (19·0)
Hungary 26 26 1 (3·8) 26 5 (19·2) 26 2 (7·7) 18 0 (0)
Ireland 6 6 1 (16·7) 6 1 (16·7) 6 1 (16·7) 18 0 (0)
Israel 34 34 4 (11·8) 34 3 (8·8) 0 ·· 17 0 (0)
Italy 192 192 77 (40·1) 149 99 (66·4) 192 2 (1·0) 16 11 (5·7)
Latvia 2 0 ·· 0 ·· 0 ·· 11 0 (0)
Lithuania 0 0 ·· 0 ·· 0 ·· 18 ··
Luxembourg 8 4 1 (25·0) 1 1 (100) 1 0 15 0 (0)
Malta 9 9 0 9 2 (22·2) 9 1 (11·1) 18 0 (0)
Montenegro 10 0 ·· 9 5 (55·6) 1 0 12 1 (10·0)
Norway 1 1 0 1 0 1 0 16 0 (0)
Poland 4 3 1 (33·3) 0 ·· 4 0 16 0 (0)
Portugal 36 0 ·· 0 ·· 0 ·· 15 8 (22·2)
Romania 61 61 43 (70·5) 61 61 (100) 61 11 (18·0) 18 8 (13·1)
Serbia 43 43 6 (14·0) 41 5 (12·2) 38 11 (13·2) 17 2 (4·6)
Slovakia 1 1 0 0 ·· 1 0 15 0 (0)
Slovenia 3 3 0 3 3 (100) 3 0 18 0 (0)
Spain 102 102 10 (9·8) 102 70 (68·6) 102 19 (18·6) 18 1 (0·9)
Macedonia 2 2 0 0 ·· 0 ·· 12 1 (50·0)
Turkey 112 66 19 (28·8) 17 4 (23·5) 27 7 (25·9) 11 24 (21·4)
UK-England and 
Northern Ireland
25 25 2 (8·0) 0 ·· 25 3 (12·0) 16 0 (0)
UK-Scotland 0 0 ·· 0 ·· 0 ·· 14 ··
Total 850 646 183 (28·3) 500 270 (54·0) 555 29 (5·2) 162 79 (9·3)
Albania, Iceland, Kosovo and Sweden did not ﬁ nd any K pneumoniae isolates that were suspected non-susceptible to carbapenems during the study period. *Mean number of antibiotics tested. 
Table 4: Resistance of conﬁ rmed carbapenemase-producing Klebsiella pneumoniae to last-line antibiotics and to all tested antibiotics
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K pneumoniae (12 [14%] of 86). Other countries with 
notable proportions of NDM-producing K pneumoniae 
were Romania (ﬁ ve [7%] of 68) and Turkey (nine [7%] of 
124). NDM-producing K pneumoniae were also isolated 
in another 12 European countries but in small numbers 
ranging between one and three isolates, though they 
were also the predominant carbapenemase-producing 
K pneumoniae isolates in Bulgaria and Denmark. In the 
case of E coli, small but noteworthy numbers of 
NDM-producing isolates were found in Bulgaria (eight 
[100%] of eight) and Serbia (ﬁ ve [100%] of ﬁ ve). Single 
isolates of NDM-producing E coli were identiﬁ ed in 
another seven countries.
VIM carbapenemases only found in K pneumoniae 
were the least frequent but represented most of the 
carbapenemase-producing isolates in Hungary (26 [72%] 
of 36) and Croatia (ﬁ ve [10%] of 48). Otherwise, only 
Greece (nine [11%] of 86) and Spain (12 [10%] of 116) had 
notable numbers of VIM-producing K pneumoniae, 
although these were also found in another seven 
countries, albeit in low numbers.
12 (33%) of the NELs tested the full panel of 
18 recom mended antibiotics. Some NELs found it diﬃ  cult 
to obtain particular compounds, others used their routine 
reference service panel, and Denmark did not report any 
antibiotic susceptibility test results. Last-line antibiotics 
tested included colistin (tested in 22 NELs), tigecycline 
(tested in 20 NELs), and fosfomycin (tested in 18 NELs).
For K pneumoniae, the proportion of isolates that were 
reported resistant to all antibiotics varied between zero 
and 29% (mean 9%, table 4). Resistance to colistin was 
reported in 183 (28%) of 646 K pneumoniae isolates, 
fosfomycin resistance in 270 (54%) of 500 isolates, and 
tigecycline resistance (according to its EUCAST 
recommended breakpoint) in only 29 (5%) of 555. High 
proportions of K pneumoniae resistant to last-line 
antibiotics were found in Italy, Romania, Turkey, and 
Spain (table 4). Of the 77 E coli with carbapenemases, 
57 were tested for susceptibility to colistin with three 
being resistant, 43 to fosfomycin (two isolates resistant), 
and 48 to tigecycline (one isolate resistant).
Carbapenem-susceptible comparator isolates of the 
same species were collected irrespective of anatomical 
site from clinical material submitted for diagnostic 
purposes from successive patients. These provided an 
important and unbiased sample, representative of the 
local susceptible population, and served as an appropriate 
control group. Univariate analysis identiﬁ ed six risk 
factors that were positively associated with carba-
penemase-producing K pneumoniae or E coli, and two 
factors that were negatively associated (appendix). Four 
of these risk factors remained signiﬁ cantly and 
independently associated with carba penemase-producing 
K pneumoniae or E coli in the multi variable model, which 
included intensive care therapy (OR=1·9, 95% CI 
1·4–2·7), hospital admission in the preceding 6 months 
(OR=2·0, 1·5–2·7), hospital-acquisition (OR=2·6, 
1·9–3·7), and travel outside the country of residence in 
the previous 6 months (OR=3·0, 1·6–5·7).
Discussion 
Clinicians increasingly depend on carbapenem anti-
biotics for the treatment of infections due to otherwise 
multidrug-resistant bacteria. CPE have been implicated 
in hospital outbreaks and have the propensity to spread 
(or disseminate their plasmids) rapidly at local, regional, 
and international levels.10–15
We provide comprehensive survey results on the 
occurrence of carbapenemase-producing K pneumoniae 
and E coli between Nov, 2013, and April, 2014, from 
455 hospitals in 34 European countries plus Turkey and 
Israel, together serving more than 270 million citizens 
out of a total population of 600 million. During the 
course of this investigation, NELs successfully expanded 
their capacity and adjusted workﬂ ows to accommodate 
new diagnostic tests.16
However, as with all sampling frameworks for bacteria 
and epidemiological data, important caveats remain. 
Despite decisions to minimise workload by concentrating 
on the two clinically most relevant species and reducing 
the amount of additional information, nine countries 
failed to recruit their quota of sentinel sites and an 
another eight countries did not provide crucial 
denominator data. In some cases this was because of 
ﬁ nancial constraints and because the workload could not 
be accommodated by some of the hospital laboratories 
that had initially agreed to participate. Some NELs with 
established routines could not manage to test additional 
antibiotics. As with other international surveillance 
systems (EARS-Net), this study relied on routinely 
available data. The precision of some of the estimates on 
the occurrence and risk factors of CPE in the European 
region could therefore still be improved. For example, 
some countries reported low numbers of index CPE 
isolates when, judging from previous publications and 
high endemicity in neighbouring countries, much higher 
rates would have been expected. In these countries, 
diagnostic habits might result in a lower sampling 
density or the recruited sentinel sites were less able to 
reliably identify carbapenem-non-susceptible isolates 
despite testing proﬁ ciency of the NELs, concealing the 
true incidence of CPE through these types of ascertain-
ment bias. Moreover, 353 (29%) of 1203 K pneumoniae 
isolates and 117 (60%) of 194 E coli isolates that were 
submitted by the sentinel hospital laboratories as 
suspected carbapenem-non-susceptible had none of the 
four major carbapenemases (KPC, NDM, OXA-48-like, 
and VIM) and were reported as other. This lack of 
speciﬁ city could be the result of a carbapenemase not 
included in the test panel, or alternative mechanisms 
such as reduced permeability. At the same time, sentinel 
laboratories relied on their local routine antibiotic 
susceptibility tests that might also be the source of 
potential misclassiﬁ cation. Nevertheless, these ﬁ rst data 
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on CPE generated in a comprehensive manner will serve 
as a benchmark against which future initiatives and 
trends will be measured.
Prevalence of carbapenemase-producing K pneumoniae 
and E coli per 10 000 hospital admissions ranged from 6·0 
in Italy, to 0·02 in Norway with an average of 1·3. The 
incidence per 100 000 hospital patient-days ranged from 
17·3 in Greece to 0·09 in Lithuania, a mean of 2·5 across 
all countries. These values will underestimate total CPE 
incidence, because carba penemases also occur in other 
Enterobacteriaceae, albeit less frequently than in Klebsiella 
spp.17 Moreover, the absence of denominator data from 
eight countries cautions against our ranking of prevalence. 
Proportions of carbapenemase-positive bacteria considered 
in this study varied between countries and between the 
two species under investigation (table 2, table 3). This 
might be the result of the diﬀ erential success of certain 
clonal lineages in diﬀ erent countries.10,14 We found a clear 
association with health care since most isolates were either 
acquired in hospital, often associated with intensive care 
treatment, or isolated from patients with previous hospital 
admission. We also found an association with previous 
travel outside the country of residence (appendix). But 
when interpreting this ﬁ nding, we must consider that 
many of the highly endemic countries could not provide 
information on previous travel, which might have led to an 
inﬂ ation of the risk estimate.
Incidence of carbapenemase-producing K pneumoniae 
and E coli was highest in southern and southeastern 
Europe. In Greece, VIM-positive K pneumoniae started to 
expand in the mid-2000s,18 but that changed with the 
rapid spread of KPC-producing K pneumoniae from 
around 2007, which subsequently became the dominant 
CPE.10 That NDM is now the second-ranking carba-
penemase in Greece is striking and raises the concern 
that there could be a further replacement event by the 
more recently expanding carbapenemase.19
Carbapenemase-producing isolates were less common 
in E coli than in K pneumoniae. KPC enzymes were 
especially rare in E coli and were only identiﬁ ed in 
countries with high proportions of KPC-producing 
K pneumoniae, where they probably reﬂ ect a spill-over of 
resistance genes from the K pneumoniae reservoir. Large 
numbers of E coli with OXA-48-like enzymes were found 
in Belgium, France, Spain, Turkey, and the UK, and 
NDM carba penemases in Bulgaria and Serbia. 
Penetration into E coli is of concern because E coli spreads 
in the com munity more readily than K pneumoniae, 
meaning that infection control interventions that mainly 
focus on hospitals are less likely to be eﬀ ective. Moreover, 
E coli from the digestive tract are common vectors for 
promiscuous plasmids, which could also accelerate epi-
demic expansion.
In Romania, eight of 12 participating hospitals 
submitted K pneumoniae isolates with OXA-48-like 
enzymes and most were genetically indistinguishable by 
DNA ﬁ ngerprinting, indicating countrywide spread of a 
single clone.20 This ﬁ nding might be analogous to the 
national expansion of K pneumoniae ST258-related clones 
with KPC-2 or KPC-3 enzymes in Greece, Italy, and 
Israel, for example, although with a diﬀ erent clonal 
lineage and carbapenemase type. OXA-48-like 
carbapenemases were frequent in Malta, Spain, France, 
and Belgium, where they appear to be repeatedly 
introduced from northern Africa. Genes coding for NDM 
seem also to be spreading in the Balkan region, with 
large numbers in Montenegro, Serbia, and Greece but 
also extending north into Slovenia and Austria. 
Surprisingly, no NDM-producing isolates were reported 
from Albania, Kosovo, or Macedonia, despite their 
occurrence in adjacent countries and reports from 
patients transferred from these countries to other 
European countries.21
Only 12 countries tested the complete panel of 
antibiotics recommended by the study protocol, which 
makes it diﬃ  cult to establish the extent to which 
extensively drug-resistant or pan-drug-resistant Entero-
bacteriaceae phenotypes prevail in European hospitals.22 
Clinically more important than these epithets are the 
proportions of carbapenemase-producing isolates that 
are also resistant to last-line antibiotics such as colistin, 
fosfomycin, and tigecycline. We generally observed that 
high-CPE-incidence countries saw more resistance to 
these last-line antibiotics as well, perhaps reﬂ ecting 
greater use and selection pressure. However, there were 
exceptions. Germany, which has a moderate CPE 
incidence, reported much higher rates of colistin and 
fosfomycin resistance than other moderate incidence 
countries. More worrying is the fact that the overall 
proportions of fosfomycin resistance (54%) and colistin 
resistance (28%) have become so high among carba-
penemase-producing K pneumoniae that even the so-
called colistin-plus treatment regimens favoured for 
infections due to CPE are increasingly jeopardised, 
leaving little choice in many cases.23,24
As exempliﬁ ed with this structured survey, the 
EuSCAPE project documented an encouraging degree of 
commitment from NELs, and shows that the political 
and logistical challenges of establishing a framework of 
enhanced sentinel surveillance for CPE can be overcome 
in Europe, Turkey, and Israel. There were large variations 
across Europe with respect to the distribution of the four 
major types of carbapenemases among clinical isolates of 
K pneumoniae and E coli. Clinicians should pay attention 
to antibiotic susceptibility testing results and be alerted 
when isolates show any degree of carbapenem non-
susceptibility, which would require conﬁ rmation of 
carbapenemase production. For most isolates, there were 
still alternative options for patient treatment; however, 
resistance to all tested antibiotics was also reported, 
which is another reminder of the urgent need for 
prevention and control of CPE in Europe and emphasises 
the need for novel antibacterial agents that are active 
against carbapenem-resistant bacteria.
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